Generate Biomedicines (NASDAQ:GENB) Shares Up 4.6% – Should You Buy?

Generate Biomedicines Inc (NASDAQ:GENB) shares traded up 4.6% during mid-day trading on Monday . The stock traded as high as $16.75 and last traded at $16.8550. 145,857 shares traded hands during trading, a decline of 78% from the average session volume of 667,813 shares. The stock had previously closed at $16.12.

Analysts Set New Price Targets

GENB has been the subject of several recent analyst reports. Weiss Ratings assumed coverage on shares of Generate Biomedicines in a research note on Tuesday, August 11th. They issued a “sell (d)” rating for the company. HC Wainwright raised their price objective on Generate Biomedicines from $16.00 to $25.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Wall Street Zen lowered Generate Biomedicines from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Finally, Morgan Stanley increased their target price on Generate Biomedicines from $20.00 to $22.00 and gave the stock an “overweight” rating in a research report on Thursday, May 14th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $25.40.

Generate Biomedicines Price Performance

The stock has a market cap of $2.62 billion and a P/E ratio of -12.82. The firm has a fifty day moving average price of $15.19.

Generate Biomedicines (NASDAQ:GENB) last issued its earnings results on Thursday, August 6th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). The firm had revenue of $6.31 million during the quarter. Equities research analysts anticipate that Generate Biomedicines Inc will post -2.29 earnings per share for the current year.

Hedge Funds Weigh In On Generate Biomedicines

A number of hedge funds have recently made changes to their positions in the business. California State Teachers Retirement System purchased a new stake in Generate Biomedicines during the 2nd quarter worth $96,000. Susquehanna International Group LLP purchased a new position in Generate Biomedicines in the second quarter valued at about $196,000. AXQ Capital LP acquired a new position in shares of Generate Biomedicines during the second quarter worth about $218,000. Bank of New York Mellon Corp purchased a new stake in shares of Generate Biomedicines in the second quarter worth about $967,000. Finally, Braidwell LP acquired a new stake in shares of Generate Biomedicines in the second quarter valued at about $55,398,000.

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.